Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer.
about
The Potential Role of the Proteases Cathepsin D and Cathepsin L in the Progression and Metastasis of Epithelial Ovarian CancerCell-cell and cell-matrix dynamics in intraperitoneal cancer metastasisEvaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells.Malignant ascites: pathophysiology and treatment.Effects of cyclooxygenase-2 gene silencing on the biological behavior of SKOV3 ovarian cancer cellsRationale and techniques of cytoreductive surgery and peritoneal chemohyperthermia.Impact of post-operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy.Diagnosis and management of peritoneal metastases from ovarian cancer.Cytoreductive surgery (SRC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of peritoneal carcinomatosis: Our initial experience and technical details.Establishment of a new representative model of human ovarian cancer in micePeritoneal dissemination of hepatoid carcinoma of the ovary treated with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy.Knockdown of cathepsin L sensitizes ovarian cancer cells to chemotherapyThe inhibitory effect of ellagic Acid on cell growth of ovarian carcinoma cells.Diagnosis and preoperative predictive value of serum HE4 concentrations for optimal debulking in epithelial ovarian cancerThe relationship between baseline nutritional status with subsequent parenteral nutrition and clinical outcomes in cancer patients undergoing hyperthermic intraperitoneal chemotherapy.The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer relapse.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer.The clinical utility of an elevated-risk multivariate index assay score in ovarian cancer patients.Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.Peritoneal metastases of rare carcinomas treated with cytoreductive surgery and HIPEC - A single center case series.Perioperative management of patients undergoing cytoreductive surgery combined with heated intraperitoneal chemotherapy for peritoneal surface malignancy: a multi-institutional experience.Morbidity, mortality, and oncological outcomes of 401 consecutive cytoreductive procedures with hyperthermic intraperitoneal chemotherapy (HIPEC).Learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies: analysis of two centres.Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.Long-term survival with peritoneal mucinous carcinomatosis from intraductal mucinous papillary pancreatic carcinoma treated with complete cytoreduction and hyperthermic intraperitoneal chemotherapy.Experimental study of antitumour activity and effects on leukocyte count of intraperitoneal administration and hyperthermic intraperitoneal chemoperfusion (HIPEC) with dioxadet in a rat model of ovarian cancer.
P2860
Q26776510-6226BFF0-5E9A-4F18-92E1-CEBD4A54A6C9Q26851836-D2025ECC-18B3-4439-9DCA-844B09DD50DAQ34161727-F316722D-74E2-4734-B2AA-FF8D8C61CFF6Q34213359-E79F4FAB-2902-4785-BE77-FE8BB5A4A5E0Q34540858-CD373407-1007-497A-A433-5B70FDD56249Q35653290-CDDD10DB-0DC9-458A-84C6-6FD81F1F61D3Q35995593-82114CB5-9AB8-40DA-9510-EAB440B1B92BQ36128985-18A4D25C-6A58-421B-94DB-AA4C916B00BBQ36160064-43EE04B2-79DE-4812-88C7-CCDBD09F6EB0Q36614305-92C8DF3A-B71E-401B-A624-ADBE73B1B395Q36953421-BF301B75-32C6-4A68-85A7-D2F244D2ADEEQ36954656-7D42334D-E5AF-4A3A-AF4E-52BE2F3A8724Q36969635-4529BF5E-2B44-4EC9-B1F9-96341C4D1474Q37093435-09A5E57D-AF27-448D-A1BC-E9E5C356C6BCQ37114979-89552D36-DA88-469D-A701-AD88FF781292Q38131754-B3BC8C28-B506-4922-9ADF-8F9F7E7F3A69Q38777716-05359049-90E9-49B3-9461-A8A368175D06Q38800078-7DE81488-CBBF-4FED-A4F2-2E2C9932CC1EQ38854853-212E6AB7-1087-4E33-BAD1-0998578C3D0CQ41454278-9A46AB17-8A7F-41C0-82EC-68804297190DQ44259666-4B805356-48A8-4D91-8617-3E2FDE22D9D3Q44841536-DB234FB5-E243-47C7-B531-15599F94E050Q47216330-9790A7DA-4696-402D-AD67-B1A7D315B32CQ47787815-71083AFD-60D6-461F-BDAB-99BBB583B952Q47809171-B99E4286-85BF-43CB-B278-0C160A6D28FCQ53486371-B25AAFC3-9E31-43A9-86D5-23AE40566127
P2860
Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Advanced cytoreduction as surg ...... in epithelial ovarian cancer.
@en
Advanced cytoreduction as surg ...... in epithelial ovarian cancer.
@nl
type
label
Advanced cytoreduction as surg ...... in epithelial ovarian cancer.
@en
Advanced cytoreduction as surg ...... in epithelial ovarian cancer.
@nl
prefLabel
Advanced cytoreduction as surg ...... in epithelial ovarian cancer.
@en
Advanced cytoreduction as surg ...... in epithelial ovarian cancer.
@nl
P2093
P50
P1476
Advanced cytoreduction as surg ...... t in epithelial ovarian cancer
@en
P2093
Antonio Macrì
E Mingrone
M R Balestra
P S Ravenda
P356
10.1016/J.EJSO.2010.11.004
P577
2010-11-26T00:00:00Z